Publication at First Faculty of Medicine |
2020
Abstract
Fremanezumab is a humanized CGRP (calcitonin gene-related peptide) antibody recently used in the specific prophylactic treatment of migraine. It binds directly to CGRP.
It has shown very good efficacy and tolerance in previous studies. In addition to reducing the monthly migraine days, it also significantly improves the quality of life in questionnaires.
Fremanezumab is registered in the Czech Republic and its payment is linked to the Centers for the Diagnosis and Treatment of Headaches. The indication criteria for the fremanezumab use are clearly specified and commented on in detail below.